Does AstraZeneca’s AZD7442 Represent the Breakthrough Treatment to Address SARS-CoV-2?

Does AstraZeneca’s AZD7442 Represent the Breakthrough Treatment to Address SARS-CoV-2

What happens if one of the promising vaccines already endorsed under emergency use authorization doesn’t work for whatever reason? What if individuals with allergic reactions are recommended not to become exposed to the vaccines. What are these people to do? What about those facing higher risks, such as the elderly in nursing homes? The U.S. government has recently expressed an imminent urgency for additional treatments targeting COVID-19. Vaccines are not enough and that’s why recently the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, in collaboration with the U.S. DoD awarded UK-based AstraZeneca $486 million to fund two major clinical trials investigating a monoclonal antibody cocktail developed originally by some brilliant scientists at Vanderbilt Vaccine Center and thereafter enhanced and strengthened by dedicated teams working tirelessly at AstraZeneca. The two Phase 3 clinical trials represent a quest to test whether it's possible to introduce to the market a therapy that serves as both Pre-Exposure Prophylaxis (PrEP) and/or Post-...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee